Cogent Biosciences, Inc.(COGT)
盘后37.120.44+1.20%19:59 EST
36.68-2.85-7.21%
行情数据延迟15分钟
- 最新
- 推荐
暂无内容公司概况
公司名称Cogent Biosciences, Inc.所属市场NASDAQ成立日期- -员工人数- -办公地址- -邮政编码- -联系电话- -联系传真- -公司概况Cogent Biosciences, Inc.成立于特拉华州。该公司是一家生物技术公司，致力于开发针对遗传疾病的精准疗法。Cogent最先进的产品PLX9486是一种高度选择性的酪氨酸激酶抑制剂，旨在有效抑制KIT D816V突变以及KIT外显子17中的其他突变。KITD816V会引发罕见的严重疾病，称为系统性肥大细胞增多症。- 01-22Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-12-29Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-12-29Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-12-29Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-12-29Form 144 - Report of proposed sale of securities关联方拟减持公告Form 144 - Report of proposed sale of securities
- 2025-12-08Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-11-19Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-11-13Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-11-12Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses[补充]招股说明书Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2025-11-10Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-11-07Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-11-03Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-09-11Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-08-05Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2025-08-05Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 分时
- 5日
- 日
- 周
- 月
数据加载中...
最高
38.93
今开
38.68
量比
1.00
最低
36.49
昨收
39.53
换手率
2.15%